Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.

Détails

ID Serval
serval:BIB_42EE55CD8DFC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Périodique
Antimicrobial Agents and Chemotherapy
Auteur(s)
Entenza J.M., Que Y.A., Vouillamoz J., Glauser M.P., Moreillon P.
ISSN
0066-4804 (Print)
ISSN-L
0066-4804
Statut éditorial
Publié
Date de publication
2001
Volume
45
Numéro
11
Pages
3076-3083
Langue
anglais
Résumé
The new 8-methoxyquinolone moxifloxacin was tested against two ciprofloxacin-susceptible Staphylococcus aureus strains (strains P8 and COL) and two ciprofloxacin-resistant derivatives of strain P8 carrying a single grlA mutation (strain P8-4) and double grlA and gyrA mutations (strain P8-128). All strains were resistant to methicillin. The MICs of ciprofloxacin and moxifloxacin were 0.5 and 0.125 mg/liter, respectively, for P8; 0.25 and 0.125 mg/liter, respectively, for COL; 8 and 0.25 mg/liter, respectively, for P8-4; and >or=128 and 2 mg/liter, respectively, for P8-128. In vitro, the rate of spontaneous resistance of P8 and COL was 10(-7) on agar plates containing ciprofloxacin at two times the MIC, whereas it was <or=10(-10) on agar plates containing moxifloxacin at two times the MIC. Rats with experimental aortic endocarditis were treated with doses of drugs that simulate the kinetics in humans: moxifloxacin, 400 mg orally once a day; ciprofloxacin, 750 mg orally twice a day; or vancomycin, 1 g intravenously twice a day. Treatment was started either 12 or 24 h after infection and lasted for 3 days. Moxifloxacin treatment resulted in culture-negative vegetations in a total of 20 of 21 (95%) rats infected with P8, 10 of 11 (91%) rats infected with COL, and 19 of 24 (79%) rats infected with P8-4 (P < 0.05 compared to the results for the controls). In contrast, ciprofloxacin treatment sterilized zero of nine (0%) vegetations infected with first-level resistant mutant P8-4. Vancomycin sterilized only 8 of 15 (53%), 6 of 11 (54%), and 12 of 23 (52%) of the vegetations, respectively. No moxifloxacin-resistant derivative emerged among these organisms. However, moxifloxacin treatment of highly ciprofloxacin-resistant mutant P8-128 failed and selected for variants for which the MIC increased two times in 2 of 10 animals. Thus, while oral moxifloxacin might deserve consideration as treatment for staphylococcal infections in humans, caution related to its use against strains for which MICs are borderline is warranted.
Mots-clé
Animals, Anti-Bacterial Agents/pharmacokinetics, Anti-Bacterial Agents/therapeutic use, Anti-Infective Agents/pharmacokinetics, Anti-Infective Agents/therapeutic use, Aza Compounds, Ciprofloxacin/pharmacokinetics, Ciprofloxacin/therapeutic use, DNA Gyrase/genetics, Drug Resistance, Microbial, Endocarditis, Bacterial/blood, Endocarditis, Bacterial/drug therapy, Fluoroquinolones, Methicillin Resistance, Microbial Sensitivity Tests, Quinolines, Rats, Spleen/microbiology, Staphylococcal Infections/blood, Staphylococcal Infections/drug therapy, Staphylococcus aureus/drug effects, Staphylococcus aureus/genetics, Vancomycin/pharmacokinetics, Vancomycin/therapeutic use
Pubmed
Web of science
Open Access
Oui
Création de la notice
07/04/2008 8:46
Dernière modification de la notice
08/05/2019 17:45
Données d'usage